Please select your country

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are therefore asked to report any suspected adverse reactions via the national reporting system found under 4.8 of the SmPC.

This website was developed by Takeda as part of a commitment made in the Risk Management Plan for Intuniv®

Date of preparation: January 2022

EXA/EUC/ELVS/0001

Please note that by selecting this icon you are agreeing to change your previously specified location. Please kindly confirm that you wish to proceed, and you will be redirected accordingly.

Confirm

Intuniv^®▼(guanfacine) Guide

Important Risk Minimisation Information for Healthcare Professionals

Please select your country

Please note that by selecting this icon you are agreeing to change your previously specified location. Please kindly confirm that you wish to proceed, and you will be redirected accordingly.

Intuniv®▼(guanfacine) Guide

Important Risk Minimisation Information for Healthcare Professionals

Please select your country

Please note that by selecting this icon you are agreeing to change your previously specified location. Please kindly confirm that you wish to proceed, and you will be redirected accordingly.

Intuniv^®▼(guanfacine) Guide